Compare M&T Bank Corporation (MTB) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
M&T Bank Corporation vs Pfizer Inc — how do they compare? M&T Bank Corporation trades at $222.43 (market cap $31.42B), while Pfizer Inc trades at $27.81 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 5× M&T Bank Corporation's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold M&T Bank Corporation for 100 Days and Pfizer Inc for 158 Days on average.
| MTB | PFE | |
|---|---|---|
Market Cap | $31.42B | $158.56B |
Volume | 1,438,219 | 44,138,282 |
Sector | Financials | Health |
52-Week High | $254.09 | $29.02 |
52-Week Low | $178.63 | $23.67 |
Typical Hold Time | 100 Days | 158 Days |
Enterprise Value | $47.77B | $210.06B |
Dividend Yield | 2.76% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
M&T Bank Corporation (MTB) trades at $216.6, down 0.98% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The bank maintains strong profitability with a 30.85% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights loan growth, AI investments, and a new branch opening, while the company declared a $1.50 dividend payable in September 2026.
The outlook is mixed: analyst consensus is a 'Buy' with a $258.92 price target implying 19.5% upside, but technical weakness and a high proportion of 'Hold' ratings suggest caution. Key risks include volatile cash flows, with a net outflow of $2.01B in 2025, and sensitivity to interest rate changes. Earnings momentum from loan growth and technology investments supports potential recovery.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
